Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
- 1 November 2003
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 25 (11) , 2972-2987
- https://doi.org/10.1016/s0149-2918(03)80348-x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Local endocrine effects of aromatase inhibitors within the breastThe Journal of Steroid Biochemistry and Molecular Biology, 2001
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability StudyJournal of Clinical Oncology, 2000
- Future possibilities in the prevention of breast cancer: Breast cancer prevention trialsBreast Cancer Research, 2000
- Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.Endocrine-Related Cancer, 1999
- Quality adjusted survival analysis with repeated quality of life measuresStatistics in Medicine, 1998
- Tamoxifen and risk of idiopathic venous thromboembolismBritish Journal of Clinical Pharmacology, 1998
- First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancerAnnals of Oncology, 1996
- A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancerAnnals of Oncology, 1996
- Estimation of Relationships for Limited Dependent VariablesEconometrica, 1958